We are live on ! Find out more
TVRD

Tvardi Therapeutics
TVRD

109 hedge funds and large institutions have $18.3M invested in Tvardi Therapeutics in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

318% more call options, than puts

Call options by funds: $46K | Put options by funds: $11K

0.13% less ownership

Funds ownership: 1.39% → 1.26% (-0.13%)

11% less funds holding

Funds holding: 122 → 109 (-13)

12% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 34

43% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 30

60% less capital invested

Capital invested by funds: $45.6M → $18.3M (-$27.2M)

Holders
109
Holders Change
-13
Holders Change %
-10.66%
% of All Funds
1.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
30
Reduced
34
Closed
30
Calls
$46K
Puts
$11K
Net Calls
+$35K
Net Calls Change
-$48K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$443K
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$433K
3
Morgan Stanley
Morgan Stanley
New York
+$305K
4
Two Sigma Investments
Two Sigma Investments
New York
+$273K
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$260K

Top Sellers

Rank Fund Capital Flow
1
ClearBridge Investments
ClearBridge Investments
New York
-$1.63M
2
IEFM
IQ EQ Fund Management
Ireland
-$1.43M
3
CWG
C WorldWide Group
Denmark
-$980K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$859K
5
PA
Pinnacle Associates
New York
-$733K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$2.64M -$177K -4,274 -4%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.95M +$37.5K +906 +1%
DGI
3
Disciplined Growth Investors
Minnesota
$1.35M +$45.7K +1,103 +2%
C
4
Chescapmanager
Maryland
$1.3M -$5.18K -125 -0.3%
FCM
5
Farallon Capital Management
California
$1.16M -$127K -3,065 -7%
State Street
6
State Street
Massachusetts
$759K +$110K +2,656 +10%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$750K +$41.5K +1,003 +4%
Federated Hermes
8
Federated Hermes
Pennsylvania
$618K +$32.6K +788 +4%
AQR Capital Management
9
AQR Capital Management
Connecticut
$616K +$209K +5,053 +28%
Renaissance Technologies
10
Renaissance Technologies
New York
$518K +$443K +10,698 +123%
Jacobs Levy Equity Management
11
Jacobs Levy Equity Management
New Jersey
$518K -$859K -20,757 -52%
Bank of America
12
Bank of America
North Carolina
$479K +$233K +5,630 +46%
Morgan Stanley
13
Morgan Stanley
New York
$436K +$305K +7,368 +83%
Verition Fund Management
14
Verition Fund Management
Connecticut
$409K +$184K +4,445 +41%
Two Sigma Advisers
15
Two Sigma Advisers
New York
$382K +$433K +10,466 +274%
Millennium Management
16
Millennium Management
New York
$347K -$353K -8,537 -40%
Northern Trust
17
Northern Trust
Illinois
$291K -$29.2K -705 -6%
Acadian Asset Management
18
Acadian Asset Management
Massachusetts
$266K +$152K +3,661 +58%
Stifel Financial
19
Stifel Financial
Missouri
$233K +$134K +3,240 +59%
Two Sigma Investments
20
Two Sigma Investments
New York
$228K +$273K +6,597 +340%
BNP Paribas Financial Markets
21
BNP Paribas Financial Markets
France
$218K +$260K +6,273 +337%
Charles Schwab
22
Charles Schwab
California
$200K -$357K -8,616 -54%
GCP
23
GSA Capital Partners
United Kingdom
$167K +$259K +6,255 New
Goldman Sachs
24
Goldman Sachs
New York
$156K +$86.3K +2,084 +56%
Assenagon Asset Management
25
Assenagon Asset Management
Luxembourg
$125K +$118K +2,840 +156%
1
2 3 4 5

TVRD Hedge Fund Activity: Q4 2023 in Review

109 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2023, worth a combined $18.3M — down 60% from $45.6M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of TVRD and 17 opened new positions — a net loss of 13 holders — while 34 trimmed existing stakes and 30 added.

The largest buyer was Renaissance Technologies, adding an estimated $443K. The largest seller was ClearBridge Investments, exiting entirely with an estimated $1.63M sold.

  • 109 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2023, down from 122 in Q3 2023.
  • Funds reported $18.3M of Tvardi Therapeutics stock for Q4 2023, down 60% quarter-over-quarter.
  • 17 funds opened new Tvardi Therapeutics positions in Q4 2023 and 30 closed out, a net change of -13 holders.
  • The largest Tvardi Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $443K added.
  • The largest Tvardi Therapeutics seller in Q4 2023 was ClearBridge Investments, an estimated $1.63M sold.

Based on aggregated 13F filings for Q4 2023.